Can You Take a GLP-1 If You Have Gastroparesis? What a New Study Found
A small 2026 Mayo Clinic study found people with slow stomach emptying had gut symptoms on GLP-1 drugs at a similar rate to people with normal emptying.

Photo: Gabriel Cox / Unsplash
When your stomach already empties slowly, you might expect a drug that slows the stomach on purpose to make things worse, and that's a fair thing to wonder about. GLP-1 drugs such as semaglutide slow stomach emptying as part of how they work, which is why doctors have treated a slow stomach as a reason for caution with them. A team at Mayo Clinic Arizona has now looked at how people whose emptying scans were already slow did after they were prescribed one. This post goes through why doctors have been cautious, what the Arizona team found, and what to watch for once a GLP-1 starts.
In the Mayo study, the 14 people with slow emptying had gut symptoms at a similar rate to the 67 with normal emptying, and among those who stopped the drug, a similar share stopped over gut symptoms. Those researchers saw nothing in their results to support strictly avoiding GLP-1s in gastroparesis, a stomach that empties too slowly with no blockage. My stance is that starting one is a reason to pay closer attention to how your gut is moving.
What gut symptoms do people get on a GLP-1?
Gut symptoms are common on these drugs, including in people whose stomach empties at a normal speed, which makes it harder to tell when a slow stomach is behind them. Cisneros and colleagues at Mayo Clinic Rochester looked back through the records of 78,277 people who started a GLP-1. Within five years, an estimated 53% had reported at least one gut symptom. That's more than half. Belly pain (28%, a little over one in four) and nausea (25%, about one in four) were the most common.
A smaller group of them had their stomach checked. Among the 696 whose symptoms on the drug led their doctor to order an emptying scan, 34.6% had delayed emptying. Put another way, about one in three of the people sent for a scan had a slow stomach, and the other two had emptying that wasn't delayed. If you're wondering which symptom might point to a slow stomach, constipation was more common in the ones with delayed emptying on their scans.
So symptoms alone make it hard for you or your prescriber to tell whether the stomach has slowed. Doctors also watch the stomach on these drugs because slowing it is part of how they work.
Why have GLP-1s been a worry with gastroparesis?
Slowing the stomach is part of what a GLP-1 is built to do. GLP-1 is a hormone your gut makes after you eat, and part of its job is to slow motility, the movement that pushes food along your digestive tract. That slowing helps you feel full. Drugs such as semaglutide are GLP-1 agonists, meaning they act like the natural hormone at its receptor, and short- and long-acting versions alike slow stomach emptying while they lower blood sugar.
Because of that built-in slowing, doctors consider gastroparesis a relative contraindication to these drugs. The term means a reason for caution that a doctor weighs against the benefits, short of a firm rule against the drug.
There is data behind the caution. Alkabbani and colleagues compared 313,342 matched pairs of adults with type 2 diabetes and no history of major gut conditions. Each pair matched one person who started a GLP-1-based drug with one who started an SGLT-2 inhibitor, a different class of diabetes medicine. Severe constipation, gastroparesis, or a blocked bowel were more common on the GLP-1-based drugs, at 1.02 cases for every 100 people followed for a year, against 0.75 on the SGLT-2 inhibitors. Per 1,000 people followed for a year, that's about 3 more cases on the GLP-1-based drugs. Half the people were followed on the drug for 5.2 months or less. Even so, the authors put the absolute risk, meaning the chance for any one person, at 1% or less. To see how people whose stomach was already slow did on these drugs, the Arizona team started from their emptying scans.
Do people with slow emptying tolerate a GLP-1 worse?
The Arizona team found no clear difference in how people with slow and normal emptying did on a GLP-1. Rolak, Hasler and colleagues looked back through the records of 81 people who had a gastric emptying scan, the test that confirms slow emptying, and were later prescribed a GLP-1. Fourteen of the 81 had delayed emptying, a small group next to the 67 whose emptying was normal. Injectable semaglutide was the drug doctors prescribed most. And both groups took similar doses, so the slow group wasn't on a gentler dose than everyone else. Half the slow group started the drug within 386 days of their scan and half the normal group within 315 days, so for the typical person, emptying was measured about ten months to a little over a year before the drug started.
If a slow stomach made a GLP-1 harder to tolerate, you'd expect more gut symptoms in the slow group. Turns out, the slow group didn't have more. Gut symptoms developed in 5 of the 14 with delayed emptying (36%, about one in three) and in 35 of the 67 with normal emptying (52%, about half). With groups of 14 and 67, that difference wasn't statistically significant, so chance could account for it.
Of the 81 people, 45 stopped the GLP-1 at some point, a little over half. Gut symptoms were the reason for 3 of the 8 who stopped in the delayed group (38%) and for 11 of the 37 who stopped in the normal group (30%), roughly one in three in each, and that difference wasn't statistically significant either. From those results, the authors suggested the drugs may be safely prescribed in many cases of gastroparesis. For what can happen to a stomach once someone is on the drug, doctors have the published case reports to go on.
A slow stomach on a GLP-1 is a reason to pay closer attention to motility and SIBO
Olubodun and colleagues gathered 12 case reports describing 13 people whose gastroparesis began or got worse on a GLP-1, in a 2026 systematic review, which means they searched for every published report on one question and summed them up together. For three of the 13, symptoms began after a dose increase, one of them after a restart at the full previous dose without working back up to it. Counting a dose raised faster than recommended and use without a prescriber's guidance as well, the reviewers put the total at four.
Nearly all 13 got better once they came off the drug. Where a repeat scan was done, emptying was back to normal in every case. Three of the 13 had signs of gastroparesis before they ever started, and all three had diabetes. One of those three was the patient whose course didn't clearly turn around. This patient already had diabetic gastroparesis with several earlier flares, and symptoms continued through the hospital stay after semaglutide was stopped, with no later improvement reported. For anyone with a known history of gastroparesis, the reviewers called for heightened caution in prescribing GLP-1s.
I see a lot of SIBO and motility problems in my clinic, and I tend to think of the slowing these drugs cause as a reason to pay attention to the motility of your gut and to try to head off side effects. These medications are still really useful for controlling blood sugar. My own conjecture is that, because GLP-1s slow gastric emptying, they might make small intestinal bacterial overgrowth (SIBO), where more bacteria live in the small intestine than it normally holds, worse in someone who already has that overgrowth. If you have diabetes too, the post on why SIBO can follow slow motility in diabetes goes through why it happens and what researchers have found so far on GLP-1s and SIBO.
Nothing is a golden ticket, and we always have to be aware of how a drug affects different groups of people, including people whose stomach already empties slowly.
I think the choice of who would benefit from a GLP-1 needs to be a little more stringent than it is now, and that choice needs to be individualized between you and your prescriber. Careful patient selection was one of the reviewers' own recommendations, along with gradual dose increases and watching for gut symptoms that don't go away. An earlier post on why 13 cases can't tell you your own risk goes through what researchers can and can't learn from a set of reports that small.
Gut changes to watch for once a GLP-1 starts
Before a GLP-1 starts, the reviewers recommend that prescribers ask about gut symptoms and any past signs of gastroparesis. Bringing your emptying scan results and a list of the gut symptoms you have now to that first visit is a good idea, so your prescriber has a starting point to compare against. Once you're on the drug, the reviewers listed the first four symptoms below as reasons for a prescriber to think early about gastroparesis from the drug, and the Rochester team found the fifth more common with delayed emptying.
- Nausea or vomiting that doesn't ease.
- Feeling full after only a few bites.
- Bloating.
- Weight loss you can't explain.
- Constipation.
You could mention any of these five to your prescriber as soon as they start or get worse, especially after a dose increase. Keep in mind, three of the 13 cases in the review began after a dose increase, so when yours began is useful for your prescriber to know.
You can take this one step at a time. Keeping an eye on your gut symptoms means that if your stomach does slow on the drug, you and your prescriber can catch it early, and in the case reports nearly everyone got better once the drug was stopped. If slow motility has already turned into SIBO for you, I laid out how I treat it, and the motility work that comes after, in the SIBO Treatment Algorithm.
FAQ
Do GLP-1 drugs slow down stomach emptying?
Yes. Slowing stomach emptying is part of how GLP-1 drugs work, along with lowering blood sugar and helping you feel full. That slowing is why doctors consider gastroparesis a relative contraindication, a reason for caution that they weigh against the benefits.
Can semaglutide cause gastroparesis?
Case reports suggest it may. A 2026 systematic review found 12 published case reports describing 13 people whose gastroparesis began or got worse on a GLP-1 drug, and semaglutide was involved in 7 of the 13, about half, though the reviewers noted that case reports can't give the true rate. In a 2026 study of 313,342 matched pairs of adults with type 2 diabetes, the authors put the absolute risk of severe gut motility problems on these drugs at 1% or less, though higher than on an SGLT-2 inhibitor.
Is gastroparesis a contraindication for GLP-1 drugs?
Doctors consider it a relative contraindication, a reason for caution that they weigh against the benefits. In a 2026 Mayo Clinic Arizona study of 81 patients, the 14 with delayed emptying had gut symptoms at a similar rate to those with normal emptying, and a similar share of those who stopped the drug did so because of gut symptoms. The authors concluded there was no support in their data for strictly avoiding GLP-1s in gastroparesis, and whether one fits your situation is something to individualize with your prescriber.
Should I stop my GLP-1 if I feel nauseous?
It's best to talk with your prescriber before changing anything, since they can help you sort out whether the nausea calls for a change. Nausea is common on these drugs. In a Mayo Clinic Rochester study of 78,277 people starting one, 25% reported nausea within five years, about one in four, second only to belly pain at 28%. Vomiting that won't stop or not being able to keep fluids down needs prompt care.
Does GLP-1 gastroparesis go away after stopping the drug?
In nearly all of the published cases, yes. In a 2026 review of 13 cases, nearly all of the patients improved once the GLP-1 was stopped, and those who had a repeat emptying scan had normal emptying again. The one exception was a patient who already had diabetic gastroparesis before starting, whose symptoms continued through the hospital stay after the drug was stopped, and the reviewers urged heightened caution for anyone with a known history of gastroparesis.
References
- 1.
- 2.
- 3.
- 4.




